# US 2026/0053732 A1 · Device for maintaining metal homeostasis, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0053732 A1
- Document ID: US20260053732A1
- Status: Published application
- Kind: A1
- Application number: 18/999,447
- Filed: 2024-12-23
- Published: 2026-02-26
- Earliest claimed: 2024-12-23
- Assignees: Mexbrain; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS)
- Applicants: Mexbrain; Universite Claude Bernard Lyon 1; Centre National De La Recherche Scientifique - Cnrs -
- Inventors: François LUX; Olivier TILLEMENT; Yannick CREMILLEUX; Thomas BRICHART; Sébastien GROYER
- Web page: https://patentgrep.com/patent/US20260053732A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 47/6939: {the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61M 1/16: with membranes
- A61M 1/1654: {Dialysates therefor}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites
- B82Y 40/00: Manufacture or treatment of nanostructures
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

A method for extracting metal cations from a biological fluid of a subject in need thereof employs dialyzing the subject with a dialysis device. The dialysis device includes a porous dialysis membrane, and a reservoir containing a perfusion fluid. At least one chelator which is either grafted on polymers or grafted on nanoparticles is present in the perfusion fluid. The cut-off threshold of the porous membrane is lower than the mass of the polymer or the nanoparticles to which the chelator is grafted. Metal cations from a biological fluid of a subject are extracted by complexing to the chelator during dialysis.

## Claims

### Claim 1

Method for extracting metal cations from a biological fluid of a subject in need thereof, comprising dialyzing said subject with a dialysis device, said dialysis device comprising:
a porous dialysis membrane, and
a reservoir containing a perfusion fluid which comprises at least one chelator:
said at least one chelator being grafted on polymers, or
said at least one chelator being grafted on nanoparticles, wherein the cut-off threshold of the porous membrane is lower than the mass of the polymer or the nanoparticle to which the at least one chelator is grafted, and wherein said metal cations from a biological fluid of a subject are extracted by complexing to said chelator during dialysis.

### Claim 2 (depends on 1)

Method according to claim 1 wherein said polymer is of more than 10 kDa.

### Claim 3 (depends on 1)

Method according to claim 1 wherein said polymer is of more than 100 kDa.

### Claim 4 (depends on 1)

Method according to claim 1 wherein said polymer is selected in the group consisting of the family of chitosans, polyacrylamides, polyamines or polycarboxylic acids.

### Claim 5 (depends on 1)

Method according to claim 1 wherein said polymer is chitosan.

### Claim 6 (depends on 1)

Method according to claim 1 wherein said nanoparticles are polysiloxane-based nanoparticles having a mean diameter greater than 3 nm.

### Claim 7 (depends on 1)

Method according to claim 1 wherein said nanoparticles are polysiloxane-based nanoparticles having a mean diameter comprised between 3 nm and 50 nm.

### Claim 8 (depends on 1)

Method according to claim 1 wherein said nanoparticles are polysiloxane-based nanoparticles having a mean size comprises between 20 kDa and 1MDa.

### Claim 9 (depends on 1)

Method according to claim 1 wherein said chelators are in a proportion between 5 and 1000 per nanoparticle.

### Claim 10 (depends on 1)

Method according to claim 1 wherein said the chelator is obtained by grafting onto the polymer or onto the nanoparticles, one of the following complexing molecules or its derivatives thereof: DOTA (1,4,7,10-tetraazacyclododecane-N, N′,N″,N′ “-tetraacetic acid), DTPA (diethylene triamine pentaacetic acid), DO3A-pyridine of formula (I),
EDTA (2,2′,2″,2″-(ethane-1,2-diyldinitrilo)tetraacetic acid), EGTA (ethylene glycol-bis (2-aminoethylether)-N, N,N′,N′-tetraacetic acid), BAPTA (1,2-bis (o-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid), NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid), DOTAGA ((2-(4,7,10-tris (carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl) pentanedioic acid), DFO (deferoxamine), amide derivatives such as for example DOTAM (1,4,7,10-tetrakis (carbamoylmethyl)-1,4,7,10 tetraazacyclododecane) or NOTAM (1,4,7-tetrakis (carbamoylmethyl)-1,4,7-triazacyclononane), as well as mixed carboxylic acid/amide derivatives, phosphonic derivatives such as DOTP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis (methylene phosphonate)) or NOTP (1,4,7-tetrakis (methylene phosphonate)-1,4,7-triazacyclononane), cyclam derivatives Docket: 13500117US2 such as TETA (1,4,8,11-tetraazacyclotetradecane-N,N′,N″,M″-tetraacetic acid), TETAM (1,4,8,11-tctraazacyclotetradecane-N,N′,N″,M″-tetrakis (carbamoylmethyl)), TETP (1,4,8,11-tetraazacyclotetradecane—and N,N′,N″,N′ “-tetrakis (methylene phosphonate)) DTPABA (diethylenetriaminepentaacetic acid bianhydride) or mixtures thereof.

### Claim 11 (depends on 1)

Method according to claim 1 wherein said the chelator is obtained by grafting onto the polymer or onto the nanoparticles DOTAGA ((2-(4,7,10-tris (carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl) pentanedioic acid).

### Claim 12 (depends on 1)

Method according to claim 1 wherein said metal cations are selected from cations of the metals Cu, Fe, Zn, Hg, Cd, Pb, Mn, Mg, Ca, Gd and Al.

### Claim 13 (depends on 1)

Method according to claim 1 wherein said metal cations are selected from cations of the metals Cu and Fe.

### Claim 14 (depends on 1)

Method according to claim 1 wherein said perfusion fluid contains trace elements selected from Calcium, Magnesium, Iron, Copper, Zinc and Manganese.

### Claim 15 (depends on 1)

Method according to claim 1 wherein said biological fluid is blood.

### Claim 16 (depends on 1)

Method according to claim 1 wherein said subject in need thereof, is suffering from a disease associated with metal overload or from a pathology related to a deregulation of metallic homeostasis.
